Applied Therapeutics, Inc. (NASDAQ:APLT) Insider Leslie D. Funtleyder Sells 22,950 Shares of Stock

Applied Therapeutics, Inc. (NASDAQ:APLT) insider Leslie D. Funtleyder sold 22,950 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $0.61, for a total transaction of $13,999.50. Following the transaction, the insider now owns 404,961 shares of the company’s stock, valued at approximately $247,026.21. This represents a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Applied Therapeutics Trading Up 0.1 %

NASDAQ:APLT opened at $0.61 on Friday. The stock’s 50-day moving average is $0.90 and its 200-day moving average is $5.14. Applied Therapeutics, Inc. has a 1-year low of $0.54 and a 1-year high of $10.62. The stock has a market cap of $70.99 million, a P/E ratio of -0.38 and a beta of 1.88.

Institutional Investors Weigh In On Applied Therapeutics

A number of institutional investors have recently added to or reduced their stakes in APLT. Sei Investments Co. bought a new stake in shares of Applied Therapeutics in the second quarter worth $535,000. The Manufacturers Life Insurance Company bought a new stake in shares of Applied Therapeutics in the 2nd quarter valued at about $172,000. Algert Global LLC acquired a new stake in shares of Applied Therapeutics in the second quarter valued at about $110,000. Hennion & Walsh Asset Management Inc. increased its stake in shares of Applied Therapeutics by 34.7% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 265,372 shares of the company’s stock valued at $2,256,000 after buying an additional 68,330 shares during the period. Finally, Intech Investment Management LLC acquired a new position in shares of Applied Therapeutics in the third quarter worth approximately $162,000. 98.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on APLT shares. William Blair cut Applied Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, December 23rd. UBS Group reissued a “neutral” rating and set a $2.00 target price (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Citigroup reduced their price target on shares of Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Robert W. Baird lowered their price objective on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, November 29th. Finally, Royal Bank of Canada cut their target price on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a research report on Friday, December 20th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Applied Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.